Petros Pharmaceuticals (PTPI) News Today $0.25 0.00 (0.00%) (As of 11/21/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Petros Pharmaceuticals Amends President’s Employment TermsOctober 21, 2024 | finance.yahoo.comPositive App Study Outcomes Enhance Prospects for Petros Pharmaceuticals’ OTC StendraSeptember 13, 2024 | markets.businessinsider.comMaxim Group Sticks to Its Buy Rating for Petros Pharmaceuticals (PTPI)August 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Petros Pharmaceuticals Amidst Promising Web App Technology and Strategic AdvancementsJuly 19, 2024 | markets.businessinsider.comPetros Pharmaceuticals Successfully Completes AI-Integrated Formative Human Factors Study Demonstrating Positive Interaction with Web App Designed for STENDRA(R) (avanafil) OTC SwitchMay 29, 2024 | finance.yahoo.comPetros Pharmaceuticals Activates Advisory Committee to Help Guide Rx-to-OTC Switch for STENDRAMay 21, 2024 | finance.yahoo.comPTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024May 16, 2024 | investorplace.comPetros Pharmaceuticals announces online distribution for lead ED product with Lemonaid HealthApril 25, 2024 | finance.yahoo.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Expands Online Distribution for Prescription STENDRA Through New Agreement with Lemonaid HealthApril 23, 2024 | finanznachrichten.dePositive Outlook for Petros Pharmaceuticals: Buy Rating Affirmed Amidst FDA Advances and Promising Stendra DevelopmentsApril 18, 2024 | markets.businessinsider.comPetros Pharma Stock Down, Despite Positive Results For Stendra StudyApril 2, 2024 | markets.businessinsider.comPTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023April 2, 2024 | investorplace.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Successfully Launches AI Tool In Collaboration with Multi-Billion-Dollar Software ProviderMarch 20, 2024 | finanznachrichten.dePetros Pharmaceuticals Inc Ordinary Shares PTPIMarch 6, 2024 | morningstar.comPetros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software ProviderFebruary 14, 2024 | finance.yahoo.comTrading was temporarily halted for "PTPI" at 09:02 AM with a stated reason of "LULD pause."February 14, 2024 | marketbeat.comPetros Pharmaceuticals Inc (PTPI)January 30, 2024 | uk.investing.comPetros Pharmaceuticals Announces Two Upcoming FDA Meetings to Review Progress and Path Forward for STENDRA(R) (avanafil) Rx-to-OTC SwitchJanuary 24, 2024 | finance.yahoo.comPetros Pharmaceuticals Demonstrates Positive Results Following Successful Completion of Initial Cohort of Phase 2 Equivalent Self-Selection Study for STENDRA (avanafil) Rx-to-OTC SwitchJanuary 17, 2024 | finance.yahoo.comBuy Rating on Petros Pharmaceuticals Amid Positive User Experience and Strategic FDA Pathway ComplianceDecember 14, 2023 | markets.businessinsider.comPetros Pharma Stock (NASDAQ:PTPI) Insider TradesDecember 12, 2023 | benzinga.comPetros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor’s (rosuvastatin) OTC Switch Technology ProviderDecember 12, 2023 | finance.yahoo.comPetros Pharmaceuticals Successfully Completes Important Study in Effort to Make STENDRA(R) (avanafil) the First Erectile Dysfunction Medication to Achieve OTC StatusDecember 12, 2023 | finance.yahoo.comMaxim Group Initiates Coverage of Petros Pharmaceuticals (PTPI) with Buy RecommendationDecember 9, 2023 | nasdaq.comPetros Pharma Stock (NASDAQ:PTPI), Analyst Ratings, Price Targets, PredictionsDecember 9, 2023 | benzinga.comPetros Pharmaceuticals initiated with bullish view at MaximDecember 8, 2023 | realmoney.thestreet.comPetros Pharmaceuticals Inc Ordinary SharesDecember 7, 2023 | morningstar.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's OTC Switch Technology ProviderDecember 5, 2023 | finanznachrichten.dePetros Pharmaceuticals Partners with Blockbuster Cholesterol Drug(1) Crestor's (rosuvastatin) OTC Switch Technology ProviderDecember 5, 2023 | finance.yahoo.comPetros Pharmaceuticals Petros Pharmaceuticals Developing Artificial Intelligence Technology for Phase 2 Equivalent Study for STENDRA(R)October 30, 2023 | finance.yahoo.comFollowing Encouraging FDA Feedback Petros Pharmaceuticals Initiates Self-Selection (Phase 2-Equivalent) Study for STENDRAOctober 19, 2023 | finance.yahoo.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA LabelOctober 4, 2023 | finanznachrichten.dePetros Pharmaceuticals Announces Positive Outcomes in Label Comprehension Study for Potential OTC STENDRA LabelOctober 4, 2023 | finance.yahoo.comPetros Pharmaceuticals to Present at the LD Micro Main Event XVISeptember 28, 2023 | finance.yahoo.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals Provides Letter to ShareholdersSeptember 11, 2023 | finanznachrichten.dePetros Pharmaceuticals Provides Letter to ShareholdersSeptember 11, 2023 | finance.yahoo.comPetros Pharmaceuticals, Inc.: Petros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 6, 2023 | finanznachrichten.dePetros Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 6, 2023 | finance.yahoo.comPetros Pharmaceuticals Down 9% After Capital Raise NewsJuly 14, 2023 | marketwatch.comPetros Pharmaceuticals Announces $15M Private PlacementJuly 13, 2023 | benzinga.comPetros Pharmaceuticals Announces Capital Raise of $15 MillionJuly 13, 2023 | finance.yahoo.comTrading was temporarily halted for "PTPI" at 11:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 11:07 AM with a stated reason of "LULD pause."July 12, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:04 AM with a stated reason of "LULD pause."April 21, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 10:04 AM with a stated reason of "LULD pause."April 20, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:04 AM with a stated reason of "LULD pause."April 20, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:04 AM with a stated reason of "LULD pause."April 18, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 10:04 AM with a stated reason of "LULD pause."April 17, 2023 | marketbeat.comTrading was temporarily halted for "PTPI" at 09:04 AM with a stated reason of "LULD pause."April 17, 2023 | marketbeat.comUS Equity Futures Mixed Ahead of Retail Sales, Industrial Production, Consumer Sentiment ReportsApril 14, 2023 | msn.com Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump’s IRS Hands Massive ‘Victory Gift’ To 401K Owners (Ad)The "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners… Claim your FREE 2024 Gold Guide PTPI Media Mentions By Week PTPI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTPI News Sentiment▼0.000.47▲Average Medical News Sentiment PTPI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTPI Articles This Week▼00▲PTPI Articles Average Week Get Petros Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for PTPI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Mustang Bio News Today Kiora Pharmaceuticals News Today Trinity Biotech News Today Conduit Pharmaceuticals News Today Senti Biosciences News Today Onconetix News Today Aytu BioPharma News Today Jaguar Health News Today Addex Therapeutics News Today RedHill Biopharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTPI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Petros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Petros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
